23andMe Admits ‘Mining’ Your DNA Data Is Its Last Hope
By Thomas Germain,
Gizmodo
| 02. 13. 2024
With the business in a tailspin, 23andMe’s CEO assures investors there’s still plenty of money it can make on your genes.
23andMe is in a death spiral. Almost everyone who wants a DNA test already bought one, a nightmare data breach ruined the company’s reputation, and 23andMe’s stock is so close to worthless it might get kicked off the Nasdaq. CEO Anne Wojcicki is on a crisis tour, promising investors the company isn’t going out of business because she has a new plan: 23andMe is going to double down on mining your DNA data and selling it to pharmaceutical companies.
“We now have the ability to mine the dataset for ourselves, as well as to partner with other groups,” Wojcicki said in an interview with Wired. “It’s a real resource that we could apply to a number of different organizations for their own drug discovery.”
That’s been part of the plan since day one, but now it looks like it’s going to happen on a much larger scale. 23andMe has always coerced its customers into giving the company...
Related Articles
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...
By Carl Zimmer, The New York Times | 05.31.2024
Last year, Jaume Pellicer led a team of fellow scientists into a forest on Grande Terre, an island east of Australia. They were in search of a fern called Tmesipteris oblanceolata. Standing just a few inches tall, it was not...
By Liz Szabo, The New York Times | 05.29.2024
By the time Rena Barrow-Wells gave birth to her fourth baby in 2020, she was well-versed in caring for a child with cystic fibrosis. She was also experienced in fighting for a diagnosis of the disease, which runs in families...
By Alison Snyder, Axios | 06.06.2024
Gene editing's next chapter will be focused on tackling cancers and more common diseases, uncovering new details about aging and other fundamental aspects of biology and editing RNA, top scientists in the field said this week.
The big picture: ...